MORGAN STANLEY PLC/CALL/ABBVIE/170/0.1/17.01.25 Stock

Warrant

DE000MB0CN17

Market Closed - Börse Stuttgart 09:53:06 2024-06-27 EDT
1.13 EUR -5.83% Intraday chart for MORGAN STANLEY PLC/CALL/ABBVIE/170/0.1/17.01.25
Current month+82.26%
1 month+105.45%
Date Price Change
24-06-27 1.13 -5.83%
24-06-26 1.2 +1.69%
24-06-25 1.18 -9.92%
24-06-24 1.31 +12.93%
24-06-21 1.16 -11.45%

Delayed Quote Börse Stuttgart

Last update June 27, 2024 at 09:53 am

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying ABBVIE INC.
Issuer Morgan Stanley
WKN MB0CN1
ISINDE000MB0CN17
Date issued 2022-11-09
Strike 170 $
Maturity 2025-01-17 (204 Days)
Parity 10 : 1
Emission price 1.9
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 2.41
Lowest since issue 0.31
Delta0.52x
Omega 7.675
Premium7.34x
Gearing14.82x
Moneyness 0.9941
Difference Strike 1.01 $
Difference Strike %+0.59%
Spread 0.01
Spread %0.93%
Theoretical value 1.065
Implied Volatility 23.55 %
Total Loss Probability 54.06 %
Intrinsic value 0.000000
Present value 1.065
Break even 181.40 €
Theta-0.02x
Vega0.05x
Rho0.04x

Company Profile

AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).
Sector
-
More about the company

Ratings for AbbVie Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: AbbVie Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
169 USD
Average target price
183.2 USD
Spread / Average Target
+8.43%
Consensus